CG Oncology director sells over $23 million in company stock By Investing.com
CG Oncology, Inc. (NASDAQ:CGON) has seen significant trading activity from one of its key insiders. Director Song Hong Fang has sold a total of 650,455 shares of the company’s common stock, according to a recent filing. The transactions, which took place on August 29, 2024, amounted to over $23 million, with the shares being sold at a price of $35.36 each.
The sale was executed in two separate transactions. In the first, 424,210 shares were sold, and in the second, 226,245 shares. Following these sales, the director still holds a considerable number of shares in the company, indicating a continued vested interest in CG Oncology’s performance.
It is important to note that the shares sold by Song Hong Fang were indirectly held through Unique Diamond Investments Limited and Charming Jade Limited, which are connected to ORI Healthcare Fund, L.P., and ORI Healthcare Fund II, L.P., respectively. These entities are part of a larger ownership structure that ultimately ties back to Song Hong Fang, as disclosed in the footnotes of the filing.
Investors often monitor insider transactions as they can provide valuable insights into the company’s health and the confidence level of its executives and directors. While the reasons behind Song Hong Fang’s decision to sell a portion of her holdings are not disclosed in the filing, the transaction does provide a glimpse into insider activity which may be of interest to current and potential shareholders.
CG Oncology, Inc. specializes in biological products and operates out of Irvine, California. As with any insider transactions, this recent sale is publicly disclosed to ensure transparency and maintain fair trading practices in the market.
In other recent news, CG Oncology has been making significant strides in the development of its drug candidate, cretostimogene. The company recently reported promising results from its Phase 2 CORE-001 trial for bladder cancer treatment, achieving a 54% complete response rate at the 24-month landmark. This study has been instrumental in highlighting the potential of cretostimogene as a non-surgical, bladder-sparing therapy.
Furthermore, CG Oncology has received a Buy rating from Roth/MKM, along with a price target of $65. This endorsement is based on the potential of cretostimogene, which is expected to be submitted for a Biologics License Application in the second half of 2025. The firm’s analysis projects over $2 billion in global sales for cretostimogene by 2033.
In addition to Roth/MKM, Goldman Sachs has also upgraded CG Oncology following the encouraging clinical trial data. The upgrade was triggered by the increased success probability in treating high-risk non-muscle invasive bladder cancer, which rose from 75% to 85%. The firm maintains a positive outlook on CG Oncology, interpreting the data as competitive against both approved and clinical-stage products.
InvestingPro Insights
In light of the recent insider trading activity at CG Oncology, Inc. (NASDAQ:CGON), investors may benefit from additional context provided by InvestingPro insights. Director Song Hong Fang’s sale of shares has prompted a closer look at the company’s financial health and market performance.
InvestingPro data indicates that CG Oncology has a market capitalization of approximately $2.46 billion. Despite the company’s substantial revenue growth of 172.68% in the last quarter, CGON’s gross profit margin appears to be under pressure, with a reported figure of -10126.34% for the last twelve months as of Q1 2024. This data point aligns with one of the InvestingPro Tips, which highlights the company’s weak gross profit margins.
Another InvestingPro Tip worth noting is that analysts do not anticipate CG Oncology will be profitable this year, which is reflected in the company’s negative P/E ratio of -7.04 and an adjusted P/E ratio of -34.25 for the last twelve months as of Q1 2024. Moreover, the company’s share price performance has been strong over the last month, with a 19.82% return, yet it is trading at a high revenue valuation multiple.
For those looking to delve deeper into CG Oncology’s financials and forecasts, there are additional InvestingPro Tips available. Currently, there are 9 more tips listed on InvestingPro that could provide further insights into CGON’s future performance and valuation (https://www.investing.com/pro/CGON).
The recent insider selling activity may raise questions among shareholders, but with the InvestingPro data and tips, investors can gain a more comprehensive understanding of CG Oncology’s financial position and market valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
